<DOC>
	<DOCNO>NCT00103519</DOCNO>
	<brief_summary>This study ass safety efficacy DITPA relative placebo patient New York Heart Association ( NYHA ) class III IV congestive heart failure ( CHF ) low serum T3 . DITPA investigational agent .</brief_summary>
	<brief_title>Study DITPA Patients With Congestive Heart Failure</brief_title>
	<detailed_description>Rationale : Congestive heart failure ( CHF ) major public health problem associate significant morbidity mortality patient New York Heart Association ( NYHA ) class III IV disease . Multiple study identify particularly high-risk group patient reduce thyroid hormone activity , specifically , low serum triiodothyronine ( T3 ) level . This group represent approximately 30 % patient NYHA class III IV disease significantly high mortality rate normal T3 . DITPA ( 3,5-diiodothyropropionic acid ) analogue naturally occur thyroid hormone ( T3 ) specifically design improve cardiac performance lower potential tachycardia CHF patient . Although structurally similar T3 , DITPA propionic acid side chain lack iodine 3 ' position outer phenolic ring . While DITPA bind thyroid hormone receptor T3 , bind affinity significantly less , suggest partial agonistic action . Preclinical study DITPA support rationale use patient CHF . Primary objective : To assess safety tolerability DITPA patient NYHA class III/IV CHF low serum T3 . Secondary Objective : To obtain preliminary evidence efficacy DITPA patient NYHA class III/IV CHF low serum T3 Design : The multi-center , randomize , double-blind , placebo-controlled study design evaluate safety tolerability DITPA patient NYHA class III IV CHF low level serum T3 normal level thyroid stimulate hormone ( TSH ) . One hundred fifty patient approximately 35 center U.S. randomize 1 3 treatment group 1:1:1 ratio ( i.e. , 50 patient per treatment group ) : - DITPA 180 mg/day ( 90 mg twice day [ BID ] , orally ) - DITPA 360 mg/day ( 180 mg BID , orally ) - Placebo BID , orally</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Greater equal 18 year age NYHA class III IV CHF Females must pregnant lactating . Females childbearing potential male must use reliable mean contraception Serum total T3 &lt; = 95 ng/dL normal level TSH On regimen consist angiotensinconverting enzyme inhibitor and/or angiotensin receptor antagonist , beta blocker , diuretic minimum 3 month prior randomization Clinically stable 2 week prior randomization ( defined change functional class NYHA , hospitalization ER visit , intravenous inotropic vasodilator treatment 2 week ) An LVEF &lt; = 40 % , document within 6 month prior randomization , &gt; 6 month confirmation LVEF local echocardiographic measurement within 2 week prior randomization Able give inform consent New onset CHF ( less 3 month prior randomization ) Active myocarditis , hypertrophic cardiomyopathy , uncorrected primary valvular disease , restrictive cardiomyopathy , uncorrected congenital heart disease , constrictive pericarditis Myocardial infarction , unstable ischemic heart disease , stroke , coronary revascularization procedure within 4 week prior randomization ; expectation coronary revascularization procedure , cardiac transplant , leave ventricular assist device placement need within 24 week randomization History sudden arrhythmic syncope sustain ventricular arrhythmia , unless patient implantable cardioverter defibrillator ( ICD ) least 12 week prior randomization ; history clinically significant heart block , unless patient pacemaker least 12 week prior randomization History cardiac resynchronization therapy last 12 week prior randomization expectation cardiac resynchronization therapy ventricular mechanical assistance need within 24 week randomization History cardiac transplant Heart rate &lt; 50 beat per minute &gt; 130 beat per minute Systolic blood pressure &lt; = 80 mm Hg Serum creatinine = &gt; 2.5 mg/dL Treatment intravenous vasodilator ( include nesiritide ) inotropes within 2 week prior randomization Receipt investigational agent device within 4 week prior randomization Diagnosis noncardiac underlie medical condition expect impact mortality within 24 week randomization Drug alcohol dependence , condition may affect study compliance History thyroid disorder form within 24 week prior randomization Use thyroid supplement ( levothyroxine , liothyronine , etc . ) preparation contain thyromimetic agent within 24 week prior randomization Supraventricular arrhythmia refractory conventional treatment , judge investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>Heart Failure , DITPA</keyword>
</DOC>